Research
CCR8-depleting antibodies restore response to radiotherapy plus anti-PD1 therapy in head and neck cancer by targeting intratumoral CCR8+ regulatory T cells
Nature ·
The Brief
- Research reports that CCR8-depleting antibodies restored response to radiotherapy plus anti-PD1 therapy in head and neck cancer.
- The approach targets intratumoral CCR8+ regulatory T cells.
- The source provided is a listing headline and title only, so further details are not available here.
Why it matters
It suggests that depleting a specific regulatory T cell population within tumours may help restore response to a combination of radiotherapy and immunotherapy.
Who’s affected
- cancer researchers
- clinicians treating head and neck cancer
- #cancer
- #immunotherapy
- #radiotherapy
- #regulatory t cells
- #head and neck cancer